US 11,084,865 B2
VEGF ANTAGONIST FORMULATIONS SUITABLE FOR INTRAVITREAL ADMINISTRATIONGeneral
US 11,084,865 B2
VEGF ANTAGONIST FORMULATIONS SUITABLE FOR INTRAVITREAL ADMINISTRATION
Tech Center:
1600 Biotechnology and Organic Chemistry
Examiner:
Christine J Saoud
Art Unit:
1647 Immunology, Receptor/Ligands, Cytokines Recombinant Hormones, and Molecular Biology
Inventors:
Eric FURFINE; Daniel DIX; Kenneth GRAHAM; Kelly FRYE
Assignee:
Priority:
06/14/07
Filed:
01/10/20
Granted:
08/10/21
Expiration:
06/14/27
Abstract
Ophthalmic formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided suitable for intravitreal administration to the eye. The ophthalmic formulations include a stable liquid formulation and a lyophilizable formulation. Preferably, the protein antagonist has an amino acid sequence of SEQ ID NO:4.
Cooperative Patent Classification (CPC)
A61A61K38/1793A61P43/00A61M5/178A61KC07K2319/30C07K